Innate Pharma SA
PAR:IPH
Innate Pharma SA
PP&E Net
Innate Pharma SA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innate Pharma SA
PAR:IPH
|
PP&E Net
€5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-2%
|
|
|
Valneva SE
PAR:VLA
|
PP&E Net
€142.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
PP&E Net
€7.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
19%
|
|
|
Inventiva SA
PAR:IVA
|
PP&E Net
€4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
PP&E Net
$16.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
22%
|
|
|
Abivax SA
PAR:ABVX
|
PP&E Net
€2.2m
|
CAGR 3-Years
178%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
Innate Pharma SA
Glance View
Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
See Also
What is Innate Pharma SA's PP&E Net?
PP&E Net
5m
EUR
Based on the financial report for Jun 30, 2025, Innate Pharma SA's PP&E Net amounts to 5m EUR.
What is Innate Pharma SA's PP&E Net growth rate?
PP&E Net CAGR 10Y
-2%
Over the last year, the PP&E Net growth was -14%. The average annual PP&E Net growth rates for Innate Pharma SA have been -20% over the past three years , -17% over the past five years , and -2% over the past ten years .
